t
Tissue Regenix Group plc announced that all resolutions were passed on a show of hands at its Annual General Meeting (AGM) held on July 23, 2025. Proxy votes for the 12 resolutions, received prior to the meeting, showed "in favour" percentages ranging from 98.54% to 99.14%. As of July 21, 2025, the total number of voting rights for the Ordinary Shares was 71,395,635.
| Date | 23 Jul 2025 |
| Time | 13:52:29 |
| Category | AGMs and other meetings |
| ID | 2810S |
Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Result of Annual Geneal Meeting
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed on a show of hands.
The results of the proxy votes received in respect of the resolutions, given to the Chair prior to the meeting, are set out below:
|
Resolution |
|
In favour |
% |
Against |
% |
Withheld |
|
1 |
Ordinary |
29,848,025 |
99.14 |
259,286 |
0.86 |
11,292 |
|
2 |
Ordinary |
29,841,588 |
99.12 |
265,703 |
0.88 |
11,312 |
|
3 |
Ordinary |
29,798,308 |
99.12 |
265,907 |
0.88 |
54,388 |
|
4 |
Ordinary |
25,110,831 |
98.94 |
268,264 |
1.06 |
4,739,508 |
|
5 |
Ordinary |
29,815,967 |
99.11 |
268,125 |
0.89 |
34,511 |
|
6 |
Ordinary |
29,798,268 |
99.12 |
265,937 |
0.88 |
54,398 |
|
7 |
Ordinary |
29,818,181 |
99.12 |
265,904 |
0.88 |
34,518 |
|
8 |
Ordinary |
29,846,958 |
99.14 |
260,338 |
0.86 |
11,307 |
|
9 |
Ordinary |
29,846,728 |
99.13 |
260,576 |
0.87 |
11,299 |
|
10 |
Ordinary |
29,670,496 |
98.66 |
401,629 |
1.34 |
46,478 |
|
11 |
Special |
29,652,870 |
98.54 |
439,135 |
1.46 |
26,598 |
|
12 |
Special |
29,847,337 |
99.14 |
259,935 |
0.86 |
11,331 |
Notes:
1. A "Vote withheld" is not counted in the calculation of the percentage of shares voted "In favour" or "Against".
2. As at 21 July 2025, being the voting deadline date in respect of the Annual General Meeting, the total number of Ordinary Shares of 0.1p each in issue and the total number of voting rights was 71,395,635.
The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 27 June 2025.
For more information:
|
Tissue Regenix Group plc |
|
|
Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
Tel: +44 (0) 20 7466 5000 |
|
Nigel Birks - Life Science Specialist Sales |
|
|
Harriet Ward - ECM |
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
Alice Woodings |
|
|
|
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.